Hydrocortisone and long-term outcomes in very-low-birthweight infants

Pediatrics International

Volumn 54, Issue 4, 2012, Pages 465-470

  Yamasaki, Chika ^a   Uchiyama, Atsushi ^a   Nakanishi, Hidehiko ^a   Masumoto, Kenichi ^a   Aoyagi, Hiroyuki ^a   Washio, Yosuke ^a   Totsu, Satsuki ^a   Imai, Ken ^a   Kusuda, Satoshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

chronic lung disease; glucocorticoid; neurodevelopmental outcome; oxygenation; preterm infants

Indexed keywords

HYDROCORTISONE;

ARTICLE; BIRTH WEIGHT; CASE CONTROL STUDY; CHILD; CHRONIC LUNG DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NERVE CELL DIFFERENTIATION; OXYGENATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; HYDROCORTISONE; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; LUNG DISEASES; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864397285     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2012.03601.x     Document Type: Article

References (21)

1. Greenough A, Cox S, Alexander J, et al,. Health care utilization of infants with chronic lung disease, related to hospitalization for RSV infection. Arch. Dis. Child. 2001; 85: 463-8. (Pubitemid 33116475)
2. Kusuda S, Fujimura M, Sakuma I, et al,. Neonatal research network, Japan: morbidity and mortality of infants with very low birth weight in Japan: center variation. Pediatrics 2006; 118: e1130-8. (Pubitemid 46393762)
3. Jeng SF, Hsu CH, Tsao PN, et al,. Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomes in very-low-birthweight infants. Dev. Med. Child Neurol. 2008; 50: 51-7.
4. Böhm B, Katz-Salamon M,. Cognitive development at 5.5 years of children with chronic lung disease of prematurity. Arch. Dis. Child. Fetal Neonatal Ed. 2003; 88: F101-5. (Pubitemid 36269529)
5. Watterberg KL, American Academy of Pediatrics, Committee on Fetus and Newborn. Policy statement: postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126: 800-8
6. Halliday HL, Ehrenkranz RA, Doyle LW,. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2010; (1): CD001146.
7. Watterberg KL, Gerdes JS, Gifford KL, Lin HM,. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999; 104: 1258-63.
8. Watterberg KL, Scott M,. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995; 95: 120-5.
9. Watterberg KL, Gerdes JS, Cook KL,. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr. Res. 2001; 50: 190-5. (Pubitemid 32701191)
10. Masumoto K, Kusuda S, Aoyagi H, et al,. Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity. Pediatr. Res. 2008; 63: 686-90.
11. Halliday HL, Ehrenkranz RA, Doyle LW,. Early (96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2001; (1): CD001146.
12. Halliday HL, Ehrenkranz RA, Doyle LW,. Moderate early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2001; (1): CD001144.
13. Halliday HL, Ehrenkranz RA, Doyle LW,. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2001; (1): CD001145.
14. Tamaru S, Kikuchi A, Takagi K, et al,. Neurodevelopmental outcomes of very low birth weight and extremely low birth weight infants at 18 months of corrected age associated with prenatal risk factors. Early Hum. Dev. 2011; 87: 55-9.
15. Harding JE, McCowan LM,. Perinatal predictors of growth patterns to 18 months in children born small for gestational age. Early Hum. Dev. 2003; 74: 13-26. (Pubitemid 37152486)
16. Watterberg KL, Shaffer ML, Mishefske MJ, et al,. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120: 40-8. (Pubitemid 47036239)
17. Lodygensky GA, Rademaker K, Zimine S, et al,. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116: 1-7.
18. Rademaker KJ, de Vries WB,. Long-term effects of neonatal hydrocortisone treatment for chronic lung disease on the developing brain and heart. Semin. Fetal. Neonatal. Med. 2009; 14: 171-7.
19. Benders MJ, Groenendaal F, van Bel F, et al,. Brain development of the preterm neonate after neonatal hydrocortisone treatment for chronic lung disease. Pediatr. Res. 2009; 66: 555-9.
20. Baud O, Laudenbach V, Evrard P, Gressens P,. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr. Res. 2001; 50: 706-11. (Pubitemid 33121639)
21. Lee BH, Stoll BJ, McDonald SA, Higgins RD, National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 2008; 121: 289-96. (Pubitemid 351198451)